SEC filing
Cue Health Files for IPO for up to $100M
The company developed its portable Cue Integrated Care Platform for molecular SARS-CoV-2 testing and received an EUA for its test in June 2020.
Sophia Genetics Increases IPO Target to $221M
The company will now offer 13 million common shares at $17 to $19 per share, raising its proceeds target from the previously announced $100 million.
Sophia Genetics Files for $100M IPO, Inks Cancer Data Deal With GE Healthcare
Sophia, which will trade on the Nasdaq, seeks to raise $100 million in an IPO, and separately announced a partnership with GE Healthcare.
Progenity Raises $40M in Private Placement
The firm said it will use the funds to support its operations, to invest in its molecular testing research and development program, and for working capital.
SeqLL Withdraws Plans for $8M IPO
The Massachusetts sequencing firm has been selling technology originally developed by Helicos BioSciences and planned to increase marketing with the IPO proceeds.